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Abstract
Background Breast cancer incidence in sub-Saharan Africa (SSA) is increasing, and SSA has the highest age-standardized 
breast cancer mortality rate worldwide. However, high-quality breast cancer data are limited in SSA.
Materials and Methods We examined breast cancer patient and tumor characteristics among women in Lilongwe, Malawi 
and evaluated risk factor associations with patient outcomes. We consecutively enrolled 100 women ≥ 18 years with newly 
diagnosed, pathologically confirmed breast cancer into a prospective longitudinal cohort with systematically assessed demo-
graphic data, HIV status, and clinical characteristics. Tumor subtypes were further determined by immunohistochemistry, 
overall survival (OS) was estimated using Kaplan–Meier methods, and hazards ratios (HR) were calculated by Cox propor-
tional hazard analyses.
Results Of the 100 participants, median age was 49 years, 19 were HIV-positive, and 75 presented with late stage (III/IV) 
disease. HER2-enriched and triple-negative/basal-like subtypes represented 17% and 25% tumors, respectively. One-year 
OS for the cohort was 74% (95% CI 62–83%). Multivariable analyses revealed mortality was associated with HIV (HR, 5.15; 
95% CI 1.58–16.76; p = 0.006), stage IV disease (HR, 8.86; 95% CI 1.07–73.25; p = 0.043), and HER2-enriched (HR, 7.46; 
95% CI 1.21–46.07; p = 0.031), and triple-negative subtypes (HR, 7.80; 95% CI 1.39–43.69; p = 0.020).
Conclusion Late stage presentation, HER2-enriched and triple-negative subtypes, and HIV coinfection were overrepresented 
in our cohort relative to resource-rich settings and were associated with mortality. These findings highlight robust opportu-
nities for population- and patient-level interventions across the entire cascade of care to improve breast cancer outcomes in 
low-income countries in SSA.
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Introduction
Breast cancer is the most common malignancy among 
women worldwide, with rising incidence and mortality 
in low- and middle-income countries (LMICs) [1]. As a 
region, sub-Saharan Africa (SSA) has one of the highest 
age-standardized breast cancer mortality rate globally (17 
per 100,000) despite lower incidence than high-income 
countries (HICs) including the United States, Australia, 
and the United Kingdom (33, 85, 94 and 94 per 100,000, 
respectively [2, 3]. This high mortality-to-incidence ratio 
is multifaceted and attributable to limited early detection 
and surveillance, advanced stage at diagnosis, and limited 
access to standard treatment modalities including targeted 
therapies [4–7].
In Malawi, a LMIC in southeastern SSA with a popula-
tion of ~ 18 Mio. and GDP per capita of $338, breast can-
cer is the fourth most commonly diagnosed cancer among 
women [8–10]. Of the ~ 18 Mio. residents of Malawi, ~ 1 
Mio. reside in the 403  km3 area of the capital, Lilongwe, 
located in the central region which primarily consists of 
Chewa (71%), Tumbuka (3.2%), and Lomwe (3.1%) tribes 
[11]. Though breast cancer represents approximately 4–7% 
of new female cancer diagnoses in Malawi, this incidence 
is predicted to increase due to population aging, ‘West-
ernization’ of lifestyles, declining morbidity and mortality 
related to infectious diseases such as HIV, and correspond-
ing rise of non-communicable diseases [8, 10, 12–15]. 
Given high HIV prevalence in SSA, HIV is a relatively 
common comorbidity among women with breast cancer 
in the region [16]. Breast cancer is a non-AIDS-defining 
cancer, and HIV infection has previously been associated 
with increased mortality among women with breast cancer 
[17], as well as advanced stage [18, 19]. Other studies, 
however, have not observed these associations [20, 21].
Despite significant recent advancements in cancer clini-
cal research capacity in Malawi [22], high-quality data 
on breast cancer are limited. These constraints are par-
tially attributed to the severe healthcare worker shortage, 
particular for cancer services, with only two Malawian 
clinical oncologists and four Malawi pathologists currently 
living and working in the country. Additionally, prior 
research has been limited to cross-sectional or retrospec-
tive studies and has lacked detailed clinical and pathologic 
characterization [23]. Thus, little is known about patient 
risk factors, tumor histological subtypes, patterns of treat-
ment response, and long-term clinical outcomes. Without 
high-quality data in these domains, breast cancer control 
efforts are severely constrained.
We report initial results from a prospective cohort of 
consecutively enrolled Malawian women with newly diag-
nosed, pathologically confirmed breast cancer at 
Kamuzu 
Central Hospital (KCH), one of two national teaching hos-
pitals, and provides cancer services for approximately half 
the country, or a catchment area of ~ 9 Mio. people. In 
the absence of rigorous, prospective, longitudinal breast 
cancer data from SSA, we describe clinical presenta-
tion, tumor immunophenotypes, treatment, and outcomes 
among women in our cohort. Our overall study aim was 
to generate foundational data for optimizing breast cancer 
management in Malawi and throughout SSA.
Methods
Patient enrollment, pathology, and clinical care
We consecutively enrolled 100 women aged 18 years or 
older with newly diagnosed, pathologically confirmed breast 
cancer in a prospective longitudinal cohort study between 
December 2016 and October 2018. The study was approved 
by the Institutional Review Board at the University of North 
Carolina at Chapel Hill and the Malawi National Health 
Science Research Committee, and all participants provided 
written informed consent at the time of enrollment.
Women with clinically suspected breast cancer underwent 
core needle biopsy. There is no routine breast cancer screen-
ing in Malawi currently, and essentially all women therefore 
presented with clinically symptomatic disease as defined by 
at least one self-reported physical breast abnormality con-
sistent with breast cancer. Tumor specimens were assessed 
in the KCH Pathology Laboratory by a dedicated Malawian 
study pathologist (T.T.). Tumor grade was determined using 
the modified Bloom-Richardson system [24]. All specimens 
were evaluated for estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 
(HER2), and Ki67 antigen by immunohistochemistry and 
scored according to the College of American Pathologist 
guidelines [25, 26]. Antibodies targeting ER (NCL-L-ER-
6F11; Novocastra, Buffalo Grove, IL, USA), PR (NCL-
L-PGR-312; Novocastra, Buffalo Grove, IL, USA), and 
HER2 (ACA342B; Biocare Medical, Pacheco, CA, USA) 
were used for receptor detection. ER and PR positivity were 
defined as ≥ 1% of tumor cell nuclei being immunoreactive 
[25]. HER2 positivity (3 +) was defined as > 30% of tumor 
cell membranes exhibiting uniform intense staining, HER2 
negativity (0 and 1 +) was defined as no staining or weak, 
and partial membrane staining in any proportion of tumor 
cells [26]. In situ hybridization (ISH) was not available 
to adjudicate equivocal cases (2 +). Following pathologic 
confirmation of invasive breast cancer, demographic and 
risk factor data were obtained through patient interviews 
and medical record review. HIV status was confirmed at the 
time of study enrollment, along with HIV viral load and 
CD4 count assessment for women who were HIV-positive. 
Patients with HIV were initiated or maintained on antiretro-
viral therapy throughout the study in collaboration with HIV 
clinicians, according to Malawi national guidelines. Breast 
cancer staging was performed using physical exam, chest 
radiography, abdominal ultrasonography, and plain radiog-
raphy as clinically indicated. Other imaging studies includ-
ing computed tomography were applied selectively, due to 
limited public sector availability and high cost. Magnetic 
resonance imaging and nuclear medicine scanning were not 
available at KCH.
Participants received treatment according to KCH insti-
tutional standards of care, which are modeled after the 
National Comprehensive Cancer Network Harmonized 
Guidelines for SSA [27]. Women with locally advanced 
tumors but without evidence of distant metastases were 
typically offered neoadjuvant chemotherapy with a goal 
of achieving adequate tumor shrinkage to facilitate surgi-
cal resection. Women with operable tumors, before or after 
chemotherapy, underwent modified radical mastectomy. 
Adjuvant and neoadjuvant chemotherapy typically included 
four to six 21-day cycles of doxorubicin plus cyclophos-
phamide followed by a single-agent taxane (paclitaxel or 
docetaxel) for three 21-day cycles. Palliative-intent chemo-
therapy generally included single-agent paclitaxel or doxoru-
bicin given in 21-day cycles. Tamoxifen was administered to 
ER/PR + women. No women received HER2-targeted treat-
ments, which are not available in the Malawi public sector.
Statistical analyses
Cohort characteristics were summarized using simple 
descriptive statistics. Categorical data were analyzed using 
Chi-squared or Fisher’s exact tests and were summarized 
using frequencies and percentages as appropriate. Continu-
ous variables were summarized using median values with 
absolute ranges. Differences between groups were evaluated 
using the non-parametric Mann–Whitney test as indicated. 
p values were 2-sided, and a p value < 0.05 was considered 
statistically significant. Kaplan–Meier curves were used to 
estimate overall survival (OS) and the log-rank test was used 
to assess differences in survival between groups. Follow-up 
time was calculated from enrollment until death, loss to fol-
low-up (LTFU), or administrative censoring on 15 January, 
2019. Adjusted and unadjusted Cox proportional hazards 
regressions were used to estimate hazard ratios (HR) and 
95% confidence intervals (CIs) to determine factors associ-
ated with mortality. For our multivariable cox regression 
model, we selected variables based on a p value < 0.2 from 
the univariable analysis or high clinical significance. Our 
multivariable analysis included age (continuous), HIV status 
(reference was negative status), stage (reference was stage 
II), and molecular subtype (reference was luminal A). Given 
a high HIV infection rate in our cohort, we also explored 
differences in patient characteristics and outcomes stratified 
by HIV status. To evaluate potential bias in OS estimates 
resulting from LTFU, additional sensitivity analyses were 
performed assuming all LTFU patients died at the time of 
their last known contact (worst case scenario). All analyses 
were conducted using STATA version 15.1 (STATA, Col-
lege Station, TX, USA) and GraphPad Prism version 8.0 
(GraphPad, San Diego, CA, USA).
Results
Patient characteristics
Between December 2016 and October 2018, 100 of 101 
eligible women with newly diagnosed breast cancer were 
enrolled in the cohort (Table 1), with only one woman with 
pathologically confirmed breast cancer at KCH declin-
ing to be enrolled. The median age was 49 years (range 
21–80 years). HIV status was determined for 99 (99%) of 
patients in which 19 (19%) were HIV-positive—4 (4%) were 
newly diagnosed with HIV at the time of enrollment and 
15 (15%) had a prior HIV diagnosis and were enrolled a 
median of 3.1 years (range, 0.1–9.9 years) after their ini-
tial HIV diagnosis. Among the 19 HIV-positive patients, 13 
had CD4 count and HIV viral load measurements performed 
at enrollment, with a median CD4 count of 466 cells/μL 
(range 101–737 cells/μL) and 10 (77%) with an HIV viral 
load < 1000 copies/mL (Table 1). Two patients had AIDS 
at the time of enrollment as defined as CD4 count < 200 
cells/μL. Seventy-eight patients presented with a palpable 
mass > 5 cm, and 28 had clinically evident tumor ulcera-
tion. Of 91 formally staged patients, 48 (53%) presented with 
stage III, and 27 (30%) presented with stage IV. No patients 
presented with stage I. Most women had T4 tumors (n = 64, 
68%), and an even higher proportion had at least N1 clinical 
lymph node involvement (n = 77, 87%).
Tumor characteristics
Histologic characterization of biopsies from all 100 women 
revealed 35 grade II tumors and 37 grade III tumors 
(Table  2). Immunophenotyping revealed 49 tumors to 
be ER + , 40 PR + , and 24 HER2 + . The Ki67 prolifera-
tion index was high in the cohort overall, evidenced by 49 
women with a Ki67 staining scored of > 15%. Based on 
immunophenotype, tumor samples were further classified 
into anticipated molecular subtypes based on the St. Gallen 
International Expert Consensus with the following results: 
23 luminal A (ER/PR + /HER2 −), 27 luminal B (ER/
PR + /HER2 + or ER/PR + /HER2-/Ki67 > 15%), 17 HER2-
enriched (ER/PR-/HER2 +), 25 triple-negative/basal-like 
(ER/PR-/HER2-), and 8 unclassifiable tumors (Table 2) [28].
Treatment
Treatment for enrolled patients is summarized in Fig. 1. 
Women initially underwent either upfront curative- or pal-
liative-intent treatment based on stage at presentation and 
tumor characteristics. Twenty-eight women immediately 
began palliative-intent treatment including one patient who 
received palliative surgery, most of whom presented with 
stage IV disease. Of 72 women eligible for curative-intent 
treatment, four patients died before receiving treatment, 
Table 1  Patient characteristics among newly diagnosed women with 




Age, years 49.2 (21–80)a
Resides outside of Lilongwe 82
Did not complete primary school 43
Earthen floor 45
Non-tap water source 38
Medical History and Risk Factors
Family history of cancer 17
Breast cancer 4
Performed prior self-breast exam(s) in past year, self-
reported
59
Age at menarche, years 15 (10–19)a
Number of pregnancies 6 (0–15)a
Ever breastfed 94
Used contraception 51
Combined oral contraception 17
Prior alcohol use 19
Prior tobacco use 8
Clinical Exam
ECOG b performance score
Score ≤ 2 98
Score > 2 2
HIV Status
Positive 19
CD4 count, cell/µL 466 (101–737)a,c





 ≤ 5 cm 20





Clinical tumor size classification
 ≤ T3 29
T4 (Direct extension to chest wall and/or skin) 64
Not recorded 7
Clinical lymph node involvement
N0 12








Table 1  (continued)
a Median, (range)
b Eastern Cooperative Oncology Group
c n = 13
Table 2  Tumor characteristics among newly diagnosed women with 
breast cancer in Lilongwe, Malawi, 2016–2018
ER estrogen receptor; PR progesterone receptor; HR +  = ER + or 
PR + ; Luminal A = HR + /HER2 − ; Luminal B = HR + /HER2 + or 
HR + /HER2 − /Ki67 > 15%; HER2-enriched = HR − , HER2 + ; Tri-













Unable to grade 3
Receptor and Ki67 Status by Immunohistochemistry
Estrogen receptor-positive (ER +) 49
Unable to assess 3
Progesterone receptor-positive (PR +) 40
Unable to assess 4
HER2-positive (HER2 +) 24
Unequivocal 2
Unable to assess 6
Ki67 ≥ 15% 49
Unable to assess 5





Unable to classify 8
three elected not to receive any cancer treatment despite 
counseling, and 65 received treatment. Among 65 women 
who received initial curative-intent treatment, 12 received 
upfront surgical intervention. Fifty-three women were eligi-
ble for possible delayed surgical intervention after neoadju-
vant treatment with adequate tumor downsizing, 35 of whom 
underwent surgery (Fig. 1).
Outcomes and cancer‑related risk factors 
for mortality
As of January 15, 2019, vital status was known for 84 of 
the 100 women enrolled in the cohort. Median OS was 
20.2 months, and 1-year OS was 74% (95% CI 62–83%). 
Sensitivity analysis incorporating worst case scenario for 
LTFU patients resulted in median OS 16.5 months and 
1-year OS was 67% (95% CI 55–76%) (Fig. 2a). Advanced
stage was associated with decreased OS (Fig. 2b; p < 0.001), 
such that one-year OS for stage II was 93% (95% CI 61–99),
for stage III was 85% (95% CI 68–93), and for stage IV was
43% (95% CI 22–63). Larger tumor size and lymph node
involvement were also associated with worse OS (Fig. 2c, d;
p = 0.018, p = 0.027). Worst case scenario sensitivity analy-
ses revealed similar associations with mortality for stage,
tumor size, and clinical lymph node involvement.
Tumor characteristics had mixed associations with mor-
tality. There was no detected relationship between histologic 
grade and mortality (p = 0.26), but immunophenotypically 
assigned molecular subtype had a significant relationship 
with OS (Fig. 2e, f; p = 0.015). One-year OS among patients 
with luminal A breast cancer was 100%, for luminal B was 
74% (95% CI 50–88%), for HER2-enriched was 60% (95% 
CI 22–84%), and for triple-negative was 57% (95% CI 
30–75%).
Cox regression analyses were used to determine whether 
specific factors were associated with increased mortality 
(Table 3). Our multivariable analysis included age, HIV 
status, stage, and molecular subtype (Table 3). Advanced 
stage was associated with mortality (HR for stage IV vs. 
stage II, 8.86; 95% CI 1.07–73.25; p = 0.043). Compared 
to patients with luminal A tumors, mortality was also asso-
ciated with having a HER2-enriched (HR, 7.46; 95% CI 
1.21–46.07; p = 0.031), and triple-negative (HR, 7.80; 95% 
CI 1.39–43.69; p = 0.020) tumor immunophenotype.
Impact of HIV
In adjusted analyses, we also found HIV status was associ-
ated with increased mortality (Table 3; HR, 5.15; 95% CI 
1.58–16.76; p = 0.006), although this was not observed in 
unadjusted analyses. Given HIV infection in 19% of our 
cohort, reflecting high seroprevalence overall in Malawi, 
we explored differences in patient characteristics and out-
comes stratified by HIV status (Table 4). The median age 
of HIV-positive and HIV-negative women was similar, and 
the distribution of tumor stage and molecular subtypes 
Fig. 1  Treatment overview among newly diagnosed women with breast cancer in Lilongwe, Malawi, 2016–2018. aDied prior to cancer treat-
ment, n = 4; Declined any cancer treatment, n = 3
Fig. 2  Overall survival (OS) among newly diagnosed women with 
breast cancer in Lilongwe, Malawi, 2016–2018, by clinical and 
pathological characteristics. a OS of the Malawi breast cancer cohort 
with sensitivity analysis demonstrating best and worst case scenarios; 
b OS by clinical stage; c OS by tumor size; d OS by clinical node 
involvement; e OS by histological grade; f OS by molecular subtype
were also comparable between both groups. Furthermore, 
HIV-positive women had a 1-year OS of 71% (95% CI 
43–87%), and HIV-negative women had a 1-year OS of 
73% (95% CI 58–84%) (Fig. 3a; p = 0.40), although explor-
atory analyses stratified by the presence of distance metas-
tases at enrollment suggested possible adverse effects of 
HIV particularly among the subgroup of women with dis-
tant metastases (Fig. 3b; p < 0.001). Since immunosurveil-
lence plays a role in breast cancer progression [29], we 
further evaluated whether a low CD4 count (< 500 cells/
μL) within our HIV-positive patients was associated with 
distant metastases, yet we did not observed a significant 
association (Fisher’s exact p = 0.075).
Discussion
Breast cancer is the most common malignancy among 
women worldwide and the fourth most common in Malawi 
[1, 8, 10]. As the first prospective breast cancer cohort in 
Malawi, and one of the first such cohorts with detailed clini-
cal and pathologic characterization from SSA, we sought to 
provide robust baseline data highlighting unique features of 
breast cancer presentation, treatment, and outcomes from a 
low-income country in the region.
Similar to other breast cancer studies in SSA, women 
in our cohort presented at a younger age and with more 
advanced disease compared to HICs. Recent efforts in 
Malawi have sought to increase breast cancer awareness 
and promote early detection through use of clinical breast 
exams [23, 30]. However, we found continued presentation 
by most women at KCH with bulky tumors often having 
associated ulceration, indicating a critical need for continued 
community education, screening, and early detection efforts 
to identify breast cancers at earlier stages. This is particu-
larly important in light of the significant, albeit expected, 
associations between mortality and clinical stage, tumor 
size, and lymph node involvement in our cohort, and the 
high 1-year OS for the minority of women diagnosed with 
stage II tumors, even with locally available public sector 
treatment in Malawi. Optimal strategies for breast cancer 
screening and early detection in SSA remain uncertain, and 
much more additional work is needed in this area to identify 
the most culturally acceptable, programmatically scalable, 
and economically efficient strategies.
In addition to advanced disease stage and young age at 
the time of diagnosis, women in SSA are more frequently 
diagnosed with biologically aggressive tumors like HER2-
enriched or TNBC [31, 32]. Our study presents the first 
description of immunophenotypically defined molecular 
subtypes from Malawi and are also among the first such data 
from SSA. To date, many breast receptor profiling studies in 
Table 3  Hazard Ratios for 
Mortality among Newly 
Diagnosed Women with Breast 
Cancer in Lilongwe, Malawi, 
2016–2018
The adjusted model includes all variables listed above
Variable Unadjusted HR [95% CI] p value Adjusted HR [95% CI] p value
Age 1.00 [0.98–1.04] 0.520 1.00 [0.96–1.04] 0.850
HIV + 1.46 [0.61–3.48] 0.401 5.15 [1.58–16.76] 0.006
Stage
II 1 (ref) 1 (ref)
III 3.11 [0.40–24.47] 0.279 1.39 [0.16–11.79] 0.761
IV 10.89 [1.44–82.50] 0.021 8.86 [1.07–73.25] 0.043
Molecular subtype
Luminal A 1 (ref) 1 (ref)
Luminal B 3.83 [0.78–18.78] 0.098 2.55 [0.47–13.70] 0.276
HER2-enriched 10.17 [1.94–53.48] 0.006 7.46 [1.21–46.07] 0.031
Triple-negative 6.91 [1.42–33.61] 0.017 7.80 [1.39–43.69] 0.020
Table 4  Baseline characteristics by HIV status among newly diag-
nosed women with breast cancer in Lilongwe, Malawi, 2016–2018
a Median (range)
b Mann Whitney test
c Chi-square test











Not recorded 8 1
Molecular subtype 0.51c
Luminal A 18 5
Luminal B 21 6
HER2-enriched 14 2
Triple-negative 22 3
Unable to classify 5 3
SSA have described women primarily from West and East 
Africa, with few reports focusing on Central and Southern 
Africa [33, 34]. Reflecting marked population and environ-
mental differences across SSA, these studies have reported 
marked variation in ER positivity (ranging from 14–70%), 
PR positivity, and HER2 positivity [34].
In our cohort, 23% of women had luminal A subtype, in 
contrast to HICs where luminal A accounts for 59–73% of 
breast cancer cases [35–37]. This is of particular significance 
since luminal A is a less aggressive subtype, can often be 
treated with endocrine therapy without chemotherapy, and 
has a high survival probability. Additionally, 17% of women 
had HER2-enriched tumors and 25% of women had triple-
negative breast cancer, which again differs from subtype 
distributions in HICs, but is similar to distributions among 
women of African descent in HICs and highlights previ-
ously described racial differences in breast cancer biology 
[37, 38].
In addition to late diagnosis and aggressive tumor biol-
ogy, our results also highlight potential adverse effects of 
limited treatment resources in the Malawi public health 
sector. Currently, the only targeted therapy available for 
breast cancer in the Malawi public sector is tamoxifen. Tras-
tuzumab is not available, similar to many SSA countries, 
despite its proven efficacy for HER2-positive breast cancers 
in HICs and recent efficacy demonstration for a trastuzumab 
biosimilar [39, 40]. Although the HER2-enriched subtype 
typically accounts for only 6% of cases in HICs [36], 17% 
of women in our cohort presented with the subtype, sim-
ilar to findings from other studies in the region [41–43]. 
Moreover, those who presented with HER2-enriched breast 
cancer among our group experienced a high mortality rate, 
underscoring a clear opportunity to improve outcomes by 
applying a proven treatment to this selected subgroup of 
patients. Although the addition of trastuzumab to current 
systemic therapies would likely improve outcomes for many 
HER2-enriched breast cancer patients, increasing access to 
this targeted therapy will require multilateral engagement 
by patient advocacy groups, development agencies, phar-
maceutical companies, and policymakers, analogous to such 
efforts for HIV.
Although breast cancer is not a malignancy with known 
HIV association, 19% of our patients were HIV-positive, 
compared with a 13% HIV infection prevalence among age-
matched women in Malawi [44]. In HICs, HIV-positive indi-
viduals have lower breast cancer incidence compared with 
HIV-negative populations [45]. However, our findings are con-
sistent with recent reports from Botswana and South Africa, 
which found 31% and 18% prevalence of HIV among women 
with breast cancer, respectively, in both instances higher than 
national HIV prevalence in the general population [42, 46]. 
As in Botswana and South Africa, HIV-infected women in our 
cohort also had typically well controlled HIV with high CD4 
counts. With increasing HIV treatment access, HIV-infected 
populations in SSA are experiencing reduced HIV-associated 
morbidity and mortality, and life expectancies are becoming 
more similar to those in HICs [47]. As in HICs, this will likely 
lead to increased risk of non-AIDS-associated comorbidities 
compared with untreated HIV-infected populations. While fur-
ther investigations are needed to determine possible epidemio-
logic links between breast cancer and HIV, the high prevalence 
of HIV in SSA and improving life expectancy for people living 
with HIV suggest that many women in the region with breast 
cancer will also be HIV-positive. Thus, elucidating potential 
effects of HIV on clinical presentations, tumor biology, treat-
ment intensity and tolerance, and outcomes is an important 
Fig. 3  Overall survival (OS) among newly diagnosed women with breast cancer in Lilongwe, Malawi, 2016–2018, by HIV status. a OS by HIV 
status; b OS by HIV status and M1 disease
regional research priority. This is especially important since 
our data and other regional reports suggest these women may 
have inferior outcomes, and data from HICs have reported 
possibly increased treatment-related infectious complications 
among HIV-positive women with breast cancer [48].
The primary strengths of our study include its prospective, 
longitudinal design, with standardized clinical and histologic 
evaluation of enrolled patients, including detailed tumor 
immunophenotyping. Women were consecutively enrolled and 
received routine care in the public sector of a national teaching 
hospital without major exclusions. LTFU rates were relatively 
low. Limitations include study conduct at a single institution 
with relatively small sample size, and the lack of detailed data 
regarding cause of death and treatment-related complications 
among enrolled women. Additionally, there is intrinsic referral 
bias among women seen at a tertiary care hospital, who may 
not represent women with breast cancer in community settings, 
especially rural areas.
In conclusion, among prospectively enrolled women with 
breast cancer in Malawi, we found young age, advanced dis-
ease, aggressive tumor biology, frequent HIV coinfection, 
and poor outcomes, relative to HICs. Advanced stage, tumor 
immunophenotype, and HIV coinfection were associated 
with mortality. These findings highlight major opportunities 
to intervene across the entire breast cancer control spectrum, 
from earlier detection to improved access to proven treatments 
to enhanced HIV co-management. It is likely only through 
such multifaceted, comprehensive efforts, that the overall goal 
of reducing morbidity and mortality from breast cancer in SSA 
can be achieved.
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